A citation-based method for searching scientific literature




Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Christian T Ruff, Ingrid A M Gause-Nilsson, Martin Fredriksson, Peter A Johansson, Anna-Maria Langkilde, Marc S Sabatine. N Engl J Med 2019
Times Cited: 1854




List of shared articles



Times cited

A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe.
S Seidu, X Cos, S Brunton, S B Harris, S P O Jansson, M Mata-Cases, A M J Neijens, P Topsever, K Khunti. Prim Care Diabetes 2021
11

Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
Alejandrina M Castañeda, Amanda Dutra-Rufato, Maria J Juarez, Luis Grosembacher, Henry Gonzalez-Torres, Carlos G Musso. Int Urol Nephrol 2021
1

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Titze. Nat Rev Nephrol 2021
17

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
12

Changing Fields-Diabetes Medications Invading the Cardiovascular Space.
Lauren D Breite, Mackenzie Steck, Brandon Tate Cutshall, Samarth P Shah, Brandon E Cave. Curr Probl Cardiol 2021
0

Latin American Expert Consensus for Comprehensive Management of Type 2 Diabetes from a Metabolic-Cardio-Renal Perspective for the Primary Care Physician.
Roopa Mehta, Daniel Pichel, Chih Hao Chen-Ku, Pablo Raffaele, Antonio Méndez Durán, Francisco Padilla, Jose Javier Arango Alvarez, José Esteban Costa Gil, Juan Esteban Gómez Mesa, Mariano Giorgi,[...]. Diabetes Ther 2021
0

Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Ryotaro Bouchi, Noriyuki Sonoda, Jun Itoh, Yasuhiro Ono, Tatsuya Fukuda, Takato Takeuchi, Junji Kishimoto, Tetsuya Yamada, Yoshihiro Ogawa. Endocr J 2021
0

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi,[...]. Sci Rep 2021
0

SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6

Glucose-Lowering Medications and Cardiovascular Outcomes.
Madhan Shanmugasundaram, J R Exequiel Pineda, Sangeetha Murugapandian. Curr Cardiol Rep 2021
1

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong,[...]. Diabetologia 2021
13

SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.
Xiaodan Wang, Jingyu Ni, Rui Guo, Lan Li, Jing Su, Feng He, Guanwei Fan. Heart Fail Rev 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
9

Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Ildiko Lingvay, Michelle Greenberg, Silvina Gallo, Harry Shi, Jie Liu, Ira Gantz. Diabetes Obes Metab 2021
2

2

Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
Qutuba G Karwi, Kim L Ho, Simran Pherwani, Ezra B Ketema, Qiu Yu Sun, Gary D Lopaschuk. Cardiovasc Res 2021
0

Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Jessica A Starr, Nathan A Pinner, Katelin M Lisenby, Alyssa Osmonson. Pharmacotherapy 2021
1


Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.
Marc Evans, Angharad R Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C Patel, Pam Brown, Wasim Hanif, Johnathan N Townend, Naresh Kanumilli,[...]. Drugs 2021
0

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
1

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease.
Masanori Wakisaka, Kuniyuki Nakamura, Toshiaki Nakano, Takanari Kitazono. J Endocr Soc 2021
0

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, Jamie P Dwyer, Avivit Cahn, Erica L Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A Murphy,[...]. Diabetes Care 2021
1

Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
Kosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada,[...]. ESC Heart Fail 2021
1

The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Jiang Liu, Jiang Tian, Komal Sodhi, Joseph I Shapiro. J Membr Biol 2021
0


The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence.
Manasvi Gupta, Shiavax Rao, Gaurav Manek, Gregg C Fonarow, Raktim K Ghosh. Ther Clin Risk Manag 2021
0


Renal effects of SGLT2 inhibitors: an update.
Josselin Nespoux, Volker Vallon. Curr Opin Nephrol Hypertens 2020
13

Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Takahiro Masuda, Shigeaki Muto, Keiko Fukuda, Minami Watanabe, Ken Ohara, Hermann Koepsell, Volker Vallon, Daisuke Nagata. Physiol Rep 2020
19

Gene knockout of the Na+-glucose cotransporter SGLT2 in a murine model of acute kidney injury induced by ischemia-reperfusion.
Josselin Nespoux, Rohit Patel, Haiyan Zhang, Winnie Huang, Brent Freeman, Paul W Sanders, Young Chul Kim, Volker Vallon. Am J Physiol Renal Physiol 2020
7


Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Christie Rampersad, Eyal Kraut, Reid H Whitlock, Paul Komenda, Vincent Woo, Claudio Rigatto, Navdeep Tangri. Am J Kidney Dis 2020
6

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, James L Januzzi, Rita R Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B Morris, Joshua J Neumiller,[...]. J Am Coll Cardiol 2020
58



Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice.
Toru Kusakabe, Shigefumi Yokota, Mika Shimizu, Takayuki Inoue, Masashi Tanaka, Ryuji Ohue-Kitano, Kazuya Muranaka, Hajime Yamakage, Hiromichi Wada, Koji Hasegawa,[...]. BMJ Open Diabetes Res Care 2020
2